Who are bivalent BNT162b2 (original/Omi BA.4/BA.5)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Low Dose PF-07328948, Tozinameran 5 to 11 Years of age, Raxtozinameran 6 months to 4 years of age, BNT162b2 BA.4/5 bivalent, BNT162b2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bivalent-bnt162b2-original-omi-ba-4-ba-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

bivalent BNT162b2 (original/Omi BA.4/BA.5) — Competitive Intelligence Brief

bivalent BNT162b2 (original/Omi BA.4/BA.5) (bivalent-bnt162b2-original-omi-ba-4-ba-5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology.

marketed mRNA vaccine SARS-CoV-2 virus Immunology Live · refreshed every 30 min

Target snapshot

bivalent BNT162b2 (original/Omi BA.4/BA.5) (bivalent-bnt162b2-original-omi-ba-4-ba-5) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bivalent BNT162b2 (original/Omi BA.4/BA.5) TARGET	bivalent-bnt162b2-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Low Dose PF-07328948	low-dose-pf-07328948	Pfizer	marketed	small molecule	SARS-CoV-2 virus
Tozinameran 5 to 11 Years of age	tozinameran-5-to-11-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 virus
Raxtozinameran 6 months to 4 years of age	raxtozinameran-6-months-to-4-years-of-age	Pfizer	marketed	viral entry inhibitor	SARS-CoV-2 virus
BNT162b2 BA.4/5 bivalent	bnt162b2-ba-4-5-bivalent	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
BNT162b2	bnt162b2	Pfizer	marketed	vaccine	SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bivalent BNT162b2 (original/Omi BA.4/BA.5) — Competitive Intelligence Brief. https://druglandscape.com/ci/bivalent-bnt162b2-original-omi-ba-4-ba-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab